---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-100388"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-04-08T23:59:59+00:00"
generated_at: "2026-06-26T08:30:14.294150+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics EVP/Chief of Clinical Affairs Morosini resigns; advisor through May 5

## Summary
- Deborah Morosini resigned as EVP and Chief of Clinical Affairs effective April 6, 2022.
- She will serve as Strategic Advisor to the President until May 5, 2022, then employment ends.
- Severance includes 3 months base salary and 3 months COBRA premium payments.
- She may provide consulting services from May 5 to November 4, 2022 on an as-needed basis.

## SEC filing metadata
- accession: 0001193125-22-100388
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-04-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312522100388/0001193125-22-100388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312522100388/d292059d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-100388
- JSON: https://secwatch.observer/filing/0001193125-22-100388.json
- Plain text: https://secwatch.observer/filing/0001193125-22-100388.txt

## Key facts
- Executive change
  Deborah Morosini resigned as EVP and Chief of Clinical Affairs at Prelude Therapeutics Inc.
  - Action: resigned
  - Role: EVP and Chief of Clinical Affairs
  source text: On April 6, 2022 (the “ Effective Date ”), Prelude Therapeutics Incorporated (the “ Company ”) and Deborah Morosini, the Company’s EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312522100388/0001193125-22-100388-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.